Infection Risks Rose With Combined Cancer Therapies
Patients on dual immunosuppressive treatments and immune checkpoint inhibitors face higher risks of serious infections.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Should patients taking multiple immunosuppressive therapies undergo more rigorous infection screening and monitoring?
A retrospective study of over 20,000 patients found that those receiving immune checkpoint inhibitors alongside multiagent immunosuppressive therapies experienced frequent, often severe infections. The findings highlight significant health risks for cancer patients managed with complex, high-intensity regimens.
Why it matters
Identifying these infection patterns is critical for oncology care teams to improve patient safety during aggressive cancer treatments. Managing these combined therapies requires careful monitoring, as nearly half of the infections identified were classified as severe or fatal.
A retrospective review analyzed 24,192 immune checkpoint inhibitor regimens administered to 20,930 patients. Among 142 patients receiving multiagent immunosuppressive therapy, researchers identified 152 infections, with hazard ratios indicating elevated risk for seniors and those with cardiac immune-related adverse events.
The players
Mass General Brigham Cancer Institute
An academic medical center specializing in oncology research, clinical care, and the study of treatment-related adverse events.
The details
Researchers utilized the Fine-Gray model to evaluate infection risk factors in patients receiving at least one supraphysiologic-dose corticosteroid and two steroid-sparing immunosuppressive therapies. This regimen, when combined with immune checkpoint inhibitors, appears to suppress immune function significantly, leading to both nonopportunistic and opportunistic infections. Patients over age 65 or those experiencing prior cardiac immune-related adverse events faced the highest relative hazards for these complications.
Timeline
June 2011 - February 2024: Study period for immune checkpoint inhibitor regimens.
September 24, 2026: Original study publication date.
Health Landscape
This research from the Mass General Brigham Cancer Institute provides essential data on managing toxicity in complex, multi-drug cancer treatment protocols. It shifts the focus toward identifying high-risk infection profiles as oncology increasingly relies on combination immunosuppressive approaches.
Patients undergoing multi-drug cancer treatments should discuss specific infection risks and symptoms with their oncology care team. It is essential to monitor for signs of illness, particularly if you are age 65 or older or have a history of cardiac-related side effects from therapy.
The takeaway
Combination cancer therapies that suppress the immune system carry significant risks of severe, life-threatening infection. Patients and caregivers should prioritize consistent communication with their medical team regarding any new symptoms during treatment.
Further reading
For more information on the evolving standards of care, see the Cancer section.
Source note: This article includes information reported by Oncology Nurse Advisor.
Live Poll
Should patients taking multiple immunosuppressive therapies undergo more rigorous infection screening and monitoring?
